Uniting Industry Leaders to Improve Global Access to Life-Changing Therapeutics
San Francisco, CA | October 7-9 – Following the resounding success of its Boston and London editions, the Operationalize: Expanded Access Programs Summit is heading West for the very first time. Taking place this July in San Francisco, this is the only dedicated West Coast event bringing together 60+ global leaders in Early Access, Expanded Access, and Post-Trial Access programs.
Why Attend?
Gain exclusive access to real-world case studies, cutting-edge program strategies, and unmatched networking opportunities with peers from companies including Eli Lilly, Gilead, Ultragenyx, Daiichi Sankyo, BridgeBio, Corcept Therapeutics, and many more.
What Makes the West Coast Edition Unique?
- Brand New Themes:
Explore emerging issues including Enhancing Patient Advocacy Relationships, Developing Transparent Exit Plans, and Cell & Gene Therapies: The Ideal Candidate for Expanded Access or an Unfeasible Proposition? - Fresh Faces & Perspectives:
Hear from new expert speakers, including former FDA officials and leaders from GE2P2 Foundation, bringing decades of regulatory and operational insights. - Unmatched Networking:
Build relationships with West Coast-based colleagues and untapped networks through 7+ hours of dedicated interaction and 3 interactive workshops designed to foster meaningful collaboration.
Whether you’re building, optimizing, or scaling your Expanded Access Programs, this Summit is your chance to stay ahead of evolving regulations, operational challenges, and patient-centric program design.
Join the conversation. Shape the future of patient access with: 60+ Expanded Access Experts, 16+ World-Class Speakers, 7+ Hours of Networking, and 3 Interactive Workshops at 1 Ultimate Dedicated Forum.
👉 Visit the event website to learn more and register: https://ter.li/3bbsyn
